Sensei Biotherapeutics (NASDAQ:FTH) Upgraded at Guggenheim

Posted by Geri Gentry on Sep 17th, 2026

Sensei Biotherapeutics (NASDAQ:FTH – Get Free Report) was upgraded by equities research analysts at Guggenheim to a “strong-buy” rating in a report released on Tuesday, Zacks reports.

Other research analysts have also issued research reports about the company. Raymond James Financial initiated coverage on Sensei Biotherapeutics in a report on Friday, July 31st. They issued an “outperform” rating and a $56.00 price target on the stock. HC Wainwright reaffirmed a “buy” rating and set a $60.00 target price on shares of Sensei Biotherapeutics in a research report on Tuesday, August 11th. Wall Street Zen upgraded Sensei Biotherapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 22nd. BTIG Research reissued a “buy” rating and issued a $55.00 price target on shares of Sensei Biotherapeutics in a research report on Thursday, July 16th. Finally, Citigroup initiated coverage on shares of Sensei Biotherapeutics in a research note on Friday, May 22nd. They set a “buy” rating and a $55.00 price target for the company. Two analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Sensei Biotherapeutics presently has an average rating of “Moderate Buy” and an average price target of $56.25.

Check Out Our Latest Stock Analysis on Sensei Biotherapeutics

Sensei Biotherapeutics Price Performance

NASDAQ:FTH opened at $34.24 on Tuesday. The firm has a market capitalization of $884.76 million, a PE ratio of -0.24 and a beta of -0.28. The business has a fifty day moving average of $31.94. Sensei Biotherapeutics has a 12 month low of $7.45 and a 12 month high of $42.14.

Sensei Biotherapeutics (NASDAQ:FTH – Get Free Report) last posted its quarterly earnings results on Tuesday, August 4th. The company reported ($2.84) earnings per share for the quarter, beating the consensus estimate of ($5.04) by $2.20. On average, research analysts forecast that Sensei Biotherapeutics will post -13.69 EPS for the current year.

Insider Buying and Selling

In related news, CFO Brian C. Stephenson bought 5,000 shares of the business’s stock in a transaction that occurred on Wednesday, July 1st. The shares were bought at an average price of $23.50 per share, with a total value of $117,500.00. Following the completion of the transaction, the chief financial officer directly owned 46,688 shares in the company, valued at approximately $1,097,168. This represents a 11.99% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Anand Kiran Parikh bought 2,806 shares of the business’s stock in a transaction that occurred on Monday, June 22nd. The shares were bought at an average cost of $19.76 per share, for a total transaction of $55,446.56. Following the transaction, the chief executive officer owned 764,234 shares of the company’s stock, valued at $15,101,263.84. The trade was a 0.37% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have acquired a total of 49,494 shares of company stock valued at $1,188,822 over the last three months. Corporate insiders own 7.00% of the company’s stock.

Hedge Funds Weigh In On Sensei Biotherapeutics

Hedge funds have recently bought and sold shares of the company. Citadel Advisors LLC bought a new stake in shares of Sensei Biotherapeutics in the 2nd quarter worth $307,000. Alyeska Investment Group L.P. bought a new position in shares of Sensei Biotherapeutics during the second quarter valued at about $3,610,000. Vivo Capital LLC purchased a new position in Sensei Biotherapeutics during the first quarter worth about $22,758,000. Bank of America Corp DE grew its position in Sensei Biotherapeutics by 10,692.5% in the 1st quarter. Bank of America Corp DE now owns 33,025 shares of the company’s stock worth $1,041,000 after purchasing an additional 32,719 shares in the last quarter. Finally, Stempoint Capital LP purchased a new stake in Sensei Biotherapeutics in the 1st quarter valued at about $4,188,000. 10.50% of the stock is owned by hedge funds and other institutional investors.

Sensei Biotherapeutics Company Profile

(Get Free Report)

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing immunotherapies for the treatment of cancer. The company’s research is centered on activating and directing the immune system to recognize and attack tumor cells.

Sensei’s technology platform is designed to generate Immune Modulating Antibodies, or IMAs, which are intended to stimulate anti-tumor immune responses by targeting mechanisms involved in immune regulation. Its development programs have included antibody-based therapies evaluated for solid tumors, including programs studied in combination with established checkpoint inhibitors.

The company was founded in 2018 and is based in Cambridge, Massachusetts.